Compare DK & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DK | MNKD |
|---|---|---|
| Founded | 2001 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2006 | 2004 |
| Metric | DK | MNKD |
|---|---|---|
| Price | $34.30 | $5.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 6 |
| Target Price | ★ $35.41 | $10.08 |
| AVG Volume (30 Days) | 1.5M | ★ 3.9M |
| Earning Date | 02-27-2026 | 02-23-2026 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | N/A | ★ 0.10 |
| Revenue | ★ $10,667,200,000.00 | $313,787,000.00 |
| Revenue This Year | N/A | $21.29 |
| Revenue Next Year | N/A | $25.53 |
| P/E Ratio | ★ N/A | $57.51 |
| Revenue Growth | N/A | ★ 17.43 |
| 52 Week Low | $11.03 | $3.38 |
| 52 Week High | $43.50 | $6.51 |
| Indicator | DK | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 57.24 | 47.64 |
| Support Level | $32.29 | $5.54 |
| Resistance Level | $34.95 | $6.05 |
| Average True Range (ATR) | 1.64 | 0.29 |
| MACD | 0.49 | -0.02 |
| Stochastic Oscillator | 68.57 | 25.88 |
Delek US Holdings Inc is an integrated energy business focused on petroleum refining, transportation and storage; wholesale crude oil, intermediate, and refined products, and convenience stores retailing. The company owns and operates independent refineries that produce a variety of petroleum products for transportation and industrial markets in the United States. It has two segments: Refining segment and Logistics segment. The logistics segment generates revenue through gathering, transporting, and storing crude oil and intermediate products, as well as by marketing, storing, and distributing refined products. The company also offers a collection of retail fuel and convenience stores operating in the Southeast region of the United States.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.